Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Rating Reiterated by Stifel Nicolaus

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)‘s stock had its “buy” rating restated by Stifel Nicolaus in a note issued to investors on Wednesday, August 30th. They currently have a $190.00 price objective on the specialty pharmaceutical company’s stock. Stifel Nicolaus’ price objective would suggest a potential upside of 25.43% from the company’s previous close.

JAZZ has been the topic of several other reports. HC Wainwright initiated coverage on Jazz Pharmaceuticals PLC in a research note on Friday, August 25th. They issued a “neutral” rating and a $144.00 target price on the stock. Cowen and Company reiterated an “outperform” rating and issued a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, June 7th. BidaskClub upgraded Jazz Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research report on Saturday, June 10th. Royal Bank Of Canada set a $210.00 price target on Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Tuesday, June 27th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $182.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, June 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and nineteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $180.96.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 151.48 on Wednesday. The firm’s 50-day moving average price is $149.01 and its 200 day moving average price is $150.05. Jazz Pharmaceuticals PLC has a one year low of $95.80 and a one year high of $163.75. The firm has a market cap of $9.10 billion, a P/E ratio of 23.33 and a beta of 1.13.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by ($0.13). The firm had revenue of $394.39 million during the quarter, compared to the consensus estimate of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The business’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.67 earnings per share. On average, equities research analysts forecast that Jazz Pharmaceuticals PLC will post $10.89 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/09/17/jazz-pharmaceuticals-plc-jazz-earns-buy-rating-from-stifel-nicolaus.html.

In other Jazz Pharmaceuticals PLC news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $153.52, for a total transaction of $153,520.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Suzanne Sawochka Hooper sold 420 shares of the company’s stock in a transaction that occurred on Friday, June 23rd. The shares were sold at an average price of $160.00, for a total value of $67,200.00. The disclosure for this sale can be found here. Insiders have sold a total of 8,717 shares of company stock valued at $1,346,617 in the last ninety days. 4.30% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of JAZZ. BlackRock Inc. grew its holdings in shares of Jazz Pharmaceuticals PLC by 3,163.9% during the 1st quarter. BlackRock Inc. now owns 3,215,159 shares of the specialty pharmaceutical company’s stock worth $466,615,000 after acquiring an additional 3,116,652 shares during the period. Janus Henderson Group PLC grew its holdings in shares of Jazz Pharmaceuticals PLC by 11,990.7% during the 2nd quarter. Janus Henderson Group PLC now owns 873,919 shares of the specialty pharmaceutical company’s stock worth $135,894,000 after acquiring an additional 866,691 shares during the period. FMR LLC grew its holdings in shares of Jazz Pharmaceuticals PLC by 11.4% during the 2nd quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock worth $1,289,159,000 after acquiring an additional 849,348 shares during the period. Janus Capital Management LLC grew its holdings in shares of Jazz Pharmaceuticals PLC by 46.8% during the 1st quarter. Janus Capital Management LLC now owns 1,470,245 shares of the specialty pharmaceutical company’s stock worth $213,367,000 after acquiring an additional 468,940 shares during the period. Finally, TIAA CREF Investment Management LLC grew its holdings in shares of Jazz Pharmaceuticals PLC by 178.2% during the 1st quarter. TIAA CREF Investment Management LLC now owns 663,548 shares of the specialty pharmaceutical company’s stock worth $96,301,000 after acquiring an additional 425,042 shares during the period. Hedge funds and other institutional investors own 88.24% of the company’s stock.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply